Ms. Martin is a senior leader, innovator, serial entrepreneur, board member and investor with deep experience in corporate strategy and business development in early and growth stage technology companies. Linda is also the President and Co-founder of Mission Cure Capital, an impact investment company focused on accelerating life-changing therapies for patients with recurrent acute and chronic pancreatitis and is Chairperson of Mission: Cure, a nonprofit organization dedicated to advancing effective therapies and developing better care models for all people suffering from pancreatitis.

MCC’s investment supports the continued development of RMS’s patented technology and novel approach to develop a revolutionary protocol to grow healthy and resilient pancreatic cells to improve the lives of people with all types of diabetes.

Mission Cure Holdings, LLC, Path BioAnalytics, Inc. and Ariel Precision Medicine, Inc. jointly announced the creation of a unique research alliance to develop innovative treatments for patients with pancreatitis, a painful disease affecting more than a million people globally and for which there is currently no treatment.